Molecular mechanisms of cisplatin resistance in bladder cancer
- 1 February 2012
- journal article
- review article
- Published by Taylor & Francis Ltd in Expert Review of Anticancer Therapy
- Vol. 12 (2), 271-281
- https://doi.org/10.1586/era.11.201
Abstract
Metastatic disease is the most common mechanism of death in patients with advanced bladder cancer. As for most solid tumors, chemotherapy remains the only realistic option for palliating or curing metastatic disease. However, bladder cancer is characterized by chemoresistance. Only modest response rates are obtained using multiagent regimens including cisplatin. These low response rates and the toxicity of these regimens limit their use to patients at highest risk. Here, we review the molecular mechanisms of cisplatin resistance. These include methods to reduce cisplatin bioavailability within a cell, and defects in the machinery that produces cell death following cisplatin-induced DNA damage. While overcoming these mechanisms is a potential therapeutic approach that can increase response rates, in the short term this knowledge could be used to predict response in individual tumors.Keywords
This publication has 111 references indexed in Scilit:
- Histone deacetylases (HDACs) in XPC gene silencing and bladder cancerJournal of Hematology & Oncology, 2011
- EGFR Nuclear Translocation Modulates DNA Repair following Cisplatin and Ionizing Radiation TreatmentCancer Research, 2011
- Distinct MicroRNA Alterations Characterize High- and Low-Grade Bladder CancerCancer Research, 2009
- Molecular disruption of RAD50 sensitizes human tumor cells to cisplatin-based chemotherapyJCI Insight, 2009
- Fibroblast Growth Factor Receptor 1 Promotes Proliferation and Survival via Activation of the Mitogen-Activated Protein Kinase Pathway in Bladder CancerCancer Research, 2009
- Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivoBritish Journal of Cancer, 2009
- Role of glutathione S-transferase P1-1 in the cellular detoxification of cisplatinMolecular Cancer Therapeutics, 2008
- Elevated Glutathione Levels Confer Cellular Sensitization to Cisplatin Toxicity by Up-Regulation of Copper Transporter hCtr1Molecular Pharmacology, 2008
- Platinum Resistance: The Role of DNA Repair PathwaysClinical Cancer Research, 2008
- Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell linesInternational Journal of Cancer, 2004